← Back to Search

Alkylating agents

laboratory biomarker analysis for Lymphoma

Phase 2
Waitlist Available
Led By Daniel O. Persky, MD
Research Sponsored by SWOG Cancer Research Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved
Approved for 30 Other Conditions

Summary

This trial will compare PET-directed chemotherapy to standard chemotherapy in treating patients with limited-stage diffuse large B-cell lymphoma.

Eligible Conditions
  • Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
Secondary study objectives
Association of Germinal Center B-cell Subtype (GCB) vs Stromal-1 vs Stromal-2 Gene Expression Signatures With PFS or Overall Survival
Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
Overall Survival of Patients With Newly Diagnosed Limited-stage Diffuse Large B-Cell Lymphoma (DLBCL)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 30 Other Conditions
This treatment demonstrated efficacy for 30 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: PET Positive: IFRT +ZevalinExperimental Treatment5 Interventions
Standard IFRT+ Zevalin IV per ABW
Group II: PET Negative: R-CHOPActive Control7 Interventions
R-CHOP x 3 Cycles
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
FDA approved
fludeoxyglucose F 18
2005
Completed Phase 3
~3970
selective external radiation therapy
2011
Completed Phase 2
~160
yttrium Y 90 ibritumomab tiuxetan
2012
Completed Phase 2
~750

Find a Location

Who is running the clinical trial?

SWOG Cancer Research NetworkLead Sponsor
396 Previous Clinical Trials
265,293 Total Patients Enrolled
37 Trials studying Lymphoma
6,901 Patients Enrolled for Lymphoma
Southwest Oncology GroupLead Sponsor
388 Previous Clinical Trials
261,028 Total Patients Enrolled
36 Trials studying Lymphoma
6,674 Patients Enrolled for Lymphoma
National Cancer Institute (NCI)NIH
13,888 Previous Clinical Trials
41,021,057 Total Patients Enrolled
1,403 Trials studying Lymphoma
382,646 Patients Enrolled for Lymphoma

Media Library

Cyclophosphamide (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT01359592 — Phase 2
Lymphoma Research Study Groups: PET Negative: R-CHOP, PET Positive: IFRT +Zevalin
Lymphoma Clinical Trial 2023: Cyclophosphamide Highlights & Side Effects. Trial Name: NCT01359592 — Phase 2
Cyclophosphamide (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01359592 — Phase 2
~11 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top